Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange

Fineline Cube Nov 5, 2024

Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering...

Company

Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024

Fineline Cube Nov 5, 2024

Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year...

Company Drug

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment

Fineline Cube Nov 5, 2024

US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent...

Company Drug

BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment

Fineline Cube Nov 5, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval...

Company Deals

Boston Scientific Corporation Announces Acquisition of Cortex, Inc.

Fineline Cube Nov 5, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement...

Medical Device Policy / Regulatory

China’s NMPA Issues Guidelines for Domestic Manufacturing of Imported Medical Devices

Fineline Cube Nov 5, 2024

The National Medical Products Administration (NMPA) has released a notification aimed at further clarifying the...

Company

Legend Biotech Corporation Appoints Alan Bash as President of Carvykti

Fineline Cube Nov 5, 2024

China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has...

Company Deals

Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology

Fineline Cube Nov 5, 2024

Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement...

Company Deals

Mirxes Holding Company Updates IPO Prospectus with 2024 Financials

Fineline Cube Nov 5, 2024

Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit...

Company Deals

Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline

Fineline Cube Nov 5, 2024

China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving...

Company Medical Device

Shanghai HeartCare Medical Technology Receives NMPA Approval for Embolization Stent

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has granted marketing approval to Shanghai HeartCare Medical Technology...

Company Deals

Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments

Fineline Cube Nov 5, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center...

Company Drug

HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment

Fineline Cube Nov 5, 2024

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...

Company Medical Device

NMPA Grants Marketing License to Abonisi Medical Technology’s Knee Joint Prosthesis System

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has issued a marketing license to Abonisi Medical Technology...

Company Drug

Isap Biotech Secures FDA IND Approval for iSAP-0909 for Bladder Cancer Imaging

Fineline Cube Nov 5, 2024

Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND)...

Company Drug

China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment

Fineline Cube Nov 5, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...

Company Digital

111 Inc. Appoints Yang “Luke” Chen to Board of Directors Following Resignation of Dr. Lian Yong Chen

Fineline Cube Nov 5, 2024

China-based online pharmacy 111 Inc. (NASDAQ: YI) has announced the appointment of its Senior Finance...

Company Deals

Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan

Fineline Cube Nov 4, 2024

Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...

Policy / Regulatory

China’s National Allied Procurement Office Launches 10th VBP Tender Round Information Filing

Fineline Cube Nov 4, 2024

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status

Fineline Cube Nov 4, 2024

The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...

Posts pagination

1 … 265 266 267 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.